B7/CD28-like target candidates:
Additional target candidates have been discovered by Compugen using the B7/CD28-like discovery platforms. These candidates are currently progressing through our therapeutically focused validation process.
Myeloid target candidates:
Our immuno-oncology target validation pipeline activities primarily focus on myeloid targets. With the aim to complement and expand the patient population responsive to checkpoints inhibitors, blocking myeloid targets may serve as the next wave of cancer immunotherapies. Several myeloid CGEN-target candidates have been identified within the tumor microenvironment of multiple cancers and are progressing through our therapeutically focused validation process.